- About Us
- Nano-Social Network
- Nano Consulting
- My Account
MedThink Communications, an innovator in health care communications and public relations, has been retained by NanoBio Corporation to promote its novel technology that uses nano-sized particles to eradicate skin infections, without harming normal tissue.
MedThink will implement a scientifically based communications program that includes public relations, advocacy development and medical communications in order to advance NanoBio's lead products, two topical agents (NB-001 and NB-002) that safely treat cold sores and toenail fungus.
"The depth of our scientific expertise allows us to transform highly technical information into readily understandable messages that resonate with a company's key audiences," said Scott Goudy, partner at MedThink. "Our scientific staff works in tandem with the promotional and public relations teams to build a comprehensive, integrated communications program."
NanoBio's scientific platform is in various stages of testing for skin infections, shingles, eye infections, vaginitis, genital herpes, and mucosal vaccines against influenza and hepatitis B. The mucosal vaccines, delivered nasally, will carry antigens that serve to alert and rouse the immune system into action against each respective infection. In the future, NanoBio plans to apply its technology to other mucosal vaccines that may include tuberculosis, small pox, anthrax and other viral and bacterial diseases.
About MedThink Communications
MedThink Communications is an award-winning, full-service medical agency whose communication services capture the essence of your brand and transform it into compelling messages that inspire your target audiences. Our innovative approach to advertising, medical communications, public relations, media planning and placement, sales training and marketing consulting serves as the perfect complement to strengthen our health care partners' competitive edge. ( http://www.medthink.com/ )
NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines, based on its patented NanoStat(TM) technology platform. Founded in 2000 as a spin-out from the Center for Biologic Nanotechnology at the University of Michigan, NanoBio's lead product candidates target treatments for herpes labialis (cold sores), onychomycosis (nail fungus) and mucosal vaccines for hepatitis B and influenza. The company's pipeline also includes products that target genital herpes, herpes zoster (shingles) and methicillin-resistant Staphylococcus aureus (MRSA).
For more information, please click here
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|